AA1
MCID: ALP039
MIFTS: 25

Alopecia Areata 1 (AA1)

Categories: Rare diseases, Skin diseases, Immune diseases

Aliases & Classifications for Alopecia Areata 1

MalaCards integrated aliases for Alopecia Areata 1:

Name: Alopecia Areata 1 57 13 73
Aa1 57

Characteristics:

OMIM:

57
Inheritance:
multifactorial

Miscellaneous:
one of the most common autoimmune diseases
may coexist with autoimmune vitiligo or thyroiditis
alopecia may spontaneously regress, become chronic, or spread diffusely


HPO:

32
alopecia areata 1:
Inheritance multifactorial inheritance


Classifications:



External Ids:

OMIM 57 104000
MedGen 42 C1863094
UMLS 73 C1863094

Summaries for Alopecia Areata 1

OMIM : 57 Alopecia areata is a genetically determined, immune-mediated disorder of the hair follicle with an estimated lifetime risk of approximately 2%, making it one of the most common human autoimmune diseases. It shows a spectrum of severity that ranges from patchy localized hair loss on the scalp to the complete absence of hair everywhere on the body (Gilhar and Kalish, 2006). (104000)

MalaCards based summary : Alopecia Areata 1, also known as aa1, is related to alopecia areata and alopecia universalis congenita. An important gene associated with Alopecia Areata 1 is AA1 (Alopecia Areata 1). The drugs Tacrolimus and Caffeine have been mentioned in the context of this disorder. Affiliated tissues include kidney, t cells and thyroid, and related phenotypes are nail pits and alopecia areata

Related Diseases for Alopecia Areata 1

Diseases in the Alopecia Areata family:

Alopecia Areata 1 Alopecia Areata 2

Diseases related to Alopecia Areata 1 via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 alopecia areata 11.1
2 alopecia universalis congenita 11.0

Symptoms & Phenotypes for Alopecia Areata 1

Symptoms via clinical synopsis from OMIM:

57
Skin Nails Hair Nails:
nail pitting
trachyonychia (rough surfaced nails)

Skin Nails Hair Hair:
patchy round or oval hair loss (alopecia areata)
alopecia totalis (entire loss of scalp hair)
alopecia universalis (entire loss of all hair on body)
peribulbar lymphocytic infiltrate (on scalp biopsy)


Clinical features from OMIM:

104000

Human phenotypes related to Alopecia Areata 1:

32 (show all 6)
# Description HPO Frequency HPO Source Accession
1 nail pits 32 HP:0001803
2 alopecia areata 32 HP:0002229
3 alopecia universalis 32 HP:0002289
4 autoimmunity 32 HP:0002960
5 alopecia totalis 32 HP:0007418
6 trachyonychia 32 HP:0030804

Drugs & Therapeutics for Alopecia Areata 1

Drugs for Alopecia Areata 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 74)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
2
Caffeine Approved, Nutraceutical Phase 4 58-08-2 2519
3 Immunosuppressive Agents Phase 4,Not Applicable
4 Calcineurin Inhibitors Phase 4,Not Applicable
5 Central Nervous System Stimulants Phase 4
6 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Phosphodiesterase Inhibitors Phase 4,Phase 2
8 Purinergic P1 Receptor Antagonists Phase 4
9
Budesonide Approved Phase 3,Phase 2 51333-22-3 63006 5281004
10
Fluticasone Approved, Experimental, Investigational Phase 3 90566-53-3 62924
11 glucocorticoids Phase 3,Phase 2,Phase 1,Not Applicable
12 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
13 Dermatologic Agents Phase 3,Not Applicable
14 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
15 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
16 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
17 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1,Not Applicable
18 Autonomic Agents Phase 3,Phase 2,Phase 1,Not Applicable
19
Glycopyrrolate Phase 3,Phase 2,Phase 1 596-51-0 3494
20 Tiotropium Bromide Phase 3 136310-93-5
21
Beclomethasone Phase 3,Phase 1 4419-39-0 20469
22 Respiratory System Agents Phase 3,Phase 2,Phase 1
23 Adjuvants, Anesthesia Phase 3,Phase 2,Phase 1
24 Adrenergic Agents Phase 3,Phase 1
25 Adrenergic Agonists Phase 3,Phase 1
26 Adrenergic beta-2 Receptor Agonists Phase 3,Phase 1
27 Adrenergic beta-Agonists Phase 3,Phase 1
28 Formoterol Fumarate Phase 3,Phase 1
29 Cholinergic Agents Phase 3,Phase 2,Phase 1
30 Muscarinic Antagonists Phase 3,Phase 2,Phase 1
31 Cholinergic Antagonists Phase 3,Phase 2,Phase 1
32 Anesthetics Phase 3,Phase 2,Phase 1
33 Parasympatholytics Phase 3
34 Anti-Allergic Agents Phase 3
35 Anti-Asthmatic Agents Phase 3,Phase 2,Phase 1
36 Anticonvulsants Phase 3,Phase 2,Phase 1
37 Bromides Phase 3,Phase 2,Phase 1
38 Bronchodilator Agents Phase 3,Phase 2,Phase 1
39 Budesonide, Formoterol Fumarate Drug Combination Phase 3
40 Poractant alfa Approved Phase 2 129069-19-8
41 Phosphodiesterase 4 Inhibitors Phase 2
42 Pulmonary Surfactants Phase 2
43
Ethanol Approved Phase 1 64-17-5 702
44
Cimetidine Approved, Investigational Phase 1 51481-61-9 2756
45
Histamine Approved, Investigational Phase 1 75614-87-8, 51-45-6 774
46 Gastrointestinal Agents Phase 1,Not Applicable
47
Histamine Phosphate Phase 1 51-74-1 65513
48 Histamine Antagonists Phase 1
49 Histamine H2 Antagonists Phase 1
50 Cytochrome P-450 CYP1A2 Inhibitors Phase 1

Interventional clinical trials:

(show all 28)
# Name Status NCT ID Phase Drugs
1 The Effects of Caffeine and L-theanine Both Alone and in Combination on Cerebral Blood Flow, Cognition and Mood Completed NCT00981955 Phase 4
2 Pharmacokinetic Study of ENVARSUS in Adult De-novo Kidney Transplant Patients Completed NCT02500212 Phase 4 ENVARSUS®;ADVAGRAF®
3 Multicentre, Open Label, Randomized, Two-arm, Parallel-group Study to Assess Efficacy and Safety of ENVARSUS® Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant Patients Completed NCT02432833 Phase 4 ENVARSUS®;PROGRAF®;ADVAGRAF®
4 2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients Completed NCT02579850 Phase 3 CHF 5993 + Ultibro matched placebo;Ultibro + CHF 5993 matched placebo
5 Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Diseas Completed NCT02467452 Phase 3 BDP/FF/GB;FlF/VI + Tiotropium
6 Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) Recruiting NCT03197818 Phase 3 CHF 5993 100/6/12.5 µg;160 µg budesonide + 4.5 µg formoterol fumarate
7 Functional Respiratory Imaging Study (FRI) Recruiting NCT03268226 Phase 3 Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium
8 A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata Not yet recruiting NCT03570749 Phase 2, Phase 3 Baricitinib;Placebo
9 Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPD Completed NCT03004417 Phase 2 CHF 6001 Dose1;CHF 6001 Dose2
10 A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPD Completed NCT02986321 Phase 2 CHF6001;Budesonide;Placebo
11 Study to Evaluate Efficacy/Safety of 4 Doses of CHF5259 Via Dry Powder Inhaler (DPI) in Patients With COPD Completed NCT02680197 Phase 2 CHF5259 or Placebo administration
12 A Double Blind, Randomized, Controlled Study to Compare CHF 5633 (Synthetic Surfactant) and Poractant Alfa in RDS Completed NCT02452476 Phase 2 CHF5633;Poractant alfa
13 Efficacy and Safety of Glycopyrrolate Bromide of COPD Patients Completed NCT02189577 Phase 2 CHF 5259;Placebo
14 A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366 Recruiting NCT03378648 Phase 1, Phase 2 CHF6366;Placebo CHF6366;umeclidinium bromide and vilanterol trifenatate
15 A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of CHF6297 in Healthy Subjects and Patients With COPD Suspended NCT02815488 Phase 1, Phase 2 CHF6297 (Part 1 - SAD);Placebo (Part 1 - SAD);CHF6297 (Part 2 - MAD);Placebo (Part 2 - MAD);CHF6297 (Part 3);Placebo (Part 3);CHF6297 (Part 4);Placebo (Part 4)
16 Motivational and Cognitive Intervention for College Drinkers Unknown status NCT01204229 Phase 1
17 A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects Completed NCT03056326 Phase 1 CHF6333 (Part 1 - SAD);Placebo (Part 1 - SAD);CHF6333 (Part 2 - MAD);Placebo (Part 2 - MAD)
18 Pharmacokinetic Interaction and the Safety of Inhaled CHF5259 and CHF6001 Completed NCT03004495 Phase 1 CHF5259 and CHF6001;CHF5259 + placebo;CHF6001 + placebo
19 Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD Patients Completed NCT02975843 Phase 1 Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium
20 A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF6001 Completed NCT02386761 Phase 1 Single Ascending Dose (SAD);Multiple Ascending Dose (MAD)
21 Drug-drug Interaction Study of CHF5993 With Cimetidine Completed NCT02287272 Phase 1 CHF 5993 pMDI;Cimetidine plus CHF5993 pMDI
22 Study to Investigate the Pharmacokinetics of CHF 6001 DPI Administered Via Nexthaler® Device or the Capsule for Oral Inhalation Via Aerolizer® Device Completed NCT02119247 Phase 1
23 Pharmacokinetics of CHF 5993 pMDI With and Without Spacer in COPD Patients Completed NCT02119234 Phase 1 Beclometasone/formoterol/glycopyrrolate;Placebo
24 A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF 5993 pMDI in Subjects With Renal Impairment. Completed NCT02040597 Phase 1 Beclometasone/Formoterol/Glycopyrrolate
25 Study of Allogeneic Bone Marrow and T-Cell Depleted, CD34+ Peripheral Blood Stem Cell Transplantation in Patients With Aplastic Anemia Unknown status NCT00017654 Not Applicable anti-thymocyte globulin;cyclophosphamide;cyclosporine;methylprednisolone
26 Outcomes and User Acceptance of the IntelliVue Alarm Advisor Software (Europe) Completed NCT03182452
27 Pediatric Arm of DZL All Age Asthma Cohort Recruiting NCT02496468
28 Functional Dyspepsia Microbiome Study Recruiting NCT02340312

Search NIH Clinical Center for Alopecia Areata 1

Genetic Tests for Alopecia Areata 1

Anatomical Context for Alopecia Areata 1

MalaCards organs/tissues related to Alopecia Areata 1:

41
Kidney, T Cells, Thyroid, Lung, Bone Marrow, Bone

Publications for Alopecia Areata 1

Variations for Alopecia Areata 1

Expression for Alopecia Areata 1

Search GEO for disease gene expression data for Alopecia Areata 1.

Pathways for Alopecia Areata 1

GO Terms for Alopecia Areata 1

Sources for Alopecia Areata 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....